Here's Won't Touch Teva: Why I Pass on the Generic Giant
Teva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
Timing bond vs index fund choices in retirement affects risk and growth. Learn when to shift allocations for income.
25,546 articlesTeva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
Elon Musk took the stand in a Delaware court as Twitter shareholders pursue damages over pre-purchase disclosures. Th...
Netflix walks away from an $83 billion Warner Bros. deal, freeing capital for expansion and content, lifting the stoc...
Egg prices have fallen sharply over the past year, easing grocery bills as households gear up for Easter. Here's what...
As Abeona prepares to report 2025 results, investors need a clear framework to interpret the numbers. This guide brea...
One transportation stock could outpace the S&P 500 in 2026 thanks to rising freight volumes, pricing power, and stron...
Iran signals a selective pass-through policy at the Strait of Hormuz, potentially tightening oil flows and boosting m...
FuboTV has faced a brutal stretch, yet new synergies from Disney and Hulu may set up a rebound in EBITDA and subscrib...
Amphastar delivered a careful Q1 2026 showing steady revenue momentum and margin discipline. This guide breaks down t...
XRP trades near key resistance as bets on the CLARITY Act shift. A May 14 committee vote could reshape price paths, w...
Institutional investors are loading up on two beaten-down software giants as AI infrastructure demand remains solid a...
Discover what the AENT 2026 earnings transcript reveals about growth, margins, and cash flow. This guide translates t...